- Company
- Becton Dickinson achieves a 90% customer satisfaction rate
- by Eo, Yun-Ho Mar 8, 2023 05:53am
- Becton Dickinson (BD Korea), a multinational medical device and equipment manufacturing company, achieved a customer satisfaction rate of 90%. The company conducted a customer satisfaction survey for domestic pharmaceutical and bio customers and announced the results on the 6th. The survey was conducted between January 9 and February 3 of thi
- Company
- Hemophilia A treatment market sales were 66 billion won
- by Kim, Jin-Gu Mar 8, 2023 05:53am
- Last year, sales of hemophilia A treatment in hospitals and clinics were tallied at 66 billion won. While existing major drugs are sluggish in hospitals and clinics, JW Pharmaceutical's Hemlibra, which recently joined the market, has risen in sales for two consecutive years, rising to No. 2 in the market. In the pharmaceutical industry, sale
- Company
- 'Vabysmo’s 4mth dosing interval may reduce patient burden'
- by Jung, Sae-Im Mar 8, 2023 05:53am
- A new drug for Neovascular (Wet) Age-Related Macular Degeneration (nAMD) that offers treatment effect with once every 4-month administration has landed in Korea. The new option is expected to greatly improve the convenience of administration in domestic patients whose number has been increasing with Korea’s aging population. Roche Korea hel
- Company
- Self-administered Kynteles lands at general hospitals
- by Eo, Yun-Ho Mar 8, 2023 05:52am
- The self-injectable formulation of the inflammatory bowel disease treatment ‘Kynteles’ can now be prescribed at general hospitals in Korea. According to industry sources, the subcutaneous injection formulation of Takeda Pharmaceuticals Korea’s Kynteles (vedolizumab) has passed the drug committee (DC) reviews in tertiary hospitals such
- Company
- Celltrion Healthcare published clinical result of Remsima SC
- by Hwang, Jin-joon Mar 8, 2023 05:51am
- Celltrion Healthcare announced on the 6th in Copenhagen, Denmark, that it was holding the '2023 European Crohn's Disease and Colitis Society (ECCO)' for four days from the 1st (local time), and 'Remsima SC' was held for the purpose of US approval. announced that it had unveiled a new global clinical trial of '. The first clinical trial is the
- Company
- Exkivity applies for reimbursement
- by Eo, Yun-Ho Mar 7, 2023 05:38am
- Exkivity, an anti-cancer drug targeting EGFR exon 20 insertion mutation, is aiming for insurance coverage. Takeda Korea recently submitted a reimbursement application for Exkivity, a treatment for non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation. This drug targets the same biomarker as Janssen's Rybrevant but differs
- Company
- Boryung officially launches Zepzelca
- by Kim, Jin-Gu Mar 6, 2023 05:56am
- Boryung announced on the 28th that it has officially launched Zepzelca, a new small-cell lung cancer drug, in Korea. Zepzelca is a new anticancer drug developed by PharmaMar S.A. It is used for metastatic small-cell lung cancer that has failed first-line platinum-based chemotherapy. Zepzelca is a new drug with a mechanism that simultaneously
- Company
- ‘No regrets...happy to have served at Daiichi Sankyo Korea'
- by Eo, Yun-Ho Mar 6, 2023 05:56am
- “I have no regrets. Although I have no specific plans set for the future, I would like to say it was a great honor to have served over 30 years at Daiichi Sankyo, and will cherish the memory forever.” Dae Jung Kim (63), President of Daiichi Sankyo Korea and the longest-serving multinational pharmaceutical company CEO in Korea, is leavin
- Company
- JAK inhibitor market jumped 2.4 times in 3 years
- by Kim, Jin-Gu Mar 3, 2023 05:57am
- The market for Janus kinase (JAK) inhibitors, an oral autoimmune disease treatment drug, has expanded 2.4 times over the past three years. In addition to Xeljanz, which was leading the market, new products such as Olumiant and Rinvoq were added, and each product actively expanded its indications. Competition between major products is also ge
- Company
- Obesity mkt grows larger than ever...Saxenda leads mkt
- by Chon, Seung-Hyun Mar 3, 2023 05:57am
- The domestic obesity treatment market grew to record an all-time high last year. Saxenda maintained its unrivaled lead for 4 consecutive years and left its competitor Qsymia far behind. According to the market research institution IQVIA on the 2nd, the obesity treatment market grew 22.4% YoY to reach KRW 175.7 billion last year. The obesity
